Jeffrey Cohen

John Vandermosten

Anita Dushyanth

Brian Jeep

- The European Patent Office (EPO) has issued an Intention to Grant a patent to Tenax Therapeutics, Inc. for the use of **levosimendan** in pulmonary hypertension resulting from heart failure with preserved ejection fraction (PH-HFpEF).  **[34956_0001654954-25-010792_tennx_ex991.htm:0]** **[34956_0001654954-25-010792_tennx_8k.htm:1]** 
- This patent will provide intellectual property protection in Europe for **TNX-103 (oral levosimendan)**, other formulations, and its active metabolites, through at least **December 2040**, with potential for further extension.  **[34956_0001654954-25-010792_tennx_ex991.htm:0]** 
- The patent covers various routes of administration, active metabolites (OR1896 and OR1855), a wide range of doses, and use in combination with other cardiovascular drugs for PH-HFpEF.  **[34956_0001654954-25-010792_tennx_ex991.htm:0]** 
- This IP protection supports the company's global intellectual property portfolio and is timely as Tenax prepares to initiate its second registrational **Phase 3 study, LEVEL-2**, which will recruit patients across Europe.  **[34956_0001654954-25-010792_tennx_ex991.htm:0]**

TENAX THERAPEUTICS (TENX)